top of page



Tanya Wragg
Apr 22, 20240 min read
31 views
0 comments


Selectively depleting the energy of cancer cells: A new therapeutic paradigm
Over the past fifty years the somatic mutation theory of cancer has emerged as the most successful explanation of the molecular phenotype...
Tanya Wragg
Apr 19, 20241 min read
17 views
0 comments


ESSENTIAL MOLECULAR
The essential molecular requirements for the transformation of normal cells into established cancer cells, with implications for a novel...
hilmarwarenius
Jun 12, 20231 min read
43 views
0 comments


FURTHER NEWS FOR SYNTHERIX
March 4th 2023 Hilmar Warenius’ Patent on new lead agent ONKONEK filed by SYNTHERIX June 7TH 2023 Peer reviewed new hypothesis about how...
hilmarwarenius
Jun 12, 20231 min read
32 views
0 comments


TECHNOLOGY DEVELOPMENT
Reaction Biology GmbH will collaborate in developiment of a specific PKM2 assay for ONKONEK activity in human cancers.
-
Mar 13, 20231 min read
14 views
0 comments


PATENT NEWS
GB2582571A describing SYNTHERIX unique Coumarin / Naphthalene/ Arginine warhead is at present in PCT in Europe and the USA. A new patent...
-
Mar 13, 20231 min read
25 views
0 comments
bottom of page